{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:57:45Z","timestamp":1760014665653,"version":"3.37.3"},"reference-count":8,"publisher":"BMJ","issue":"24","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1136\/heartjnl-2017-312909","type":"journal-article","created":{"date-parts":[[2018,5,14]],"date-time":"2018-05-14T16:25:29Z","timestamp":1526315129000},"page":"1993-1994","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Cochrane corner: adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia"],"prefix":"10.1136","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9960-7587","authenticated-orcid":false,"given":"Samer","family":"Alabed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Provid\u00eancia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim J A","family":"Chico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,5,14]]},"reference":[{"key":"2020050721424934000_104.24.1993.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)00422-1"},{"key":"2020050721424934000_104.24.1993.2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.17.e112"},{"key":"2020050721424934000_104.24.1993.3","first-page":"CD005154","article-title":"Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia","volume":"10","author":"Alabed","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2020050721424934000_104.24.1993.4","doi-asserted-by":"crossref","unstructured":"Holdgate A , Foo A . Adenosine versus intravenous calcium channel antagonists for the treatment of supraventricular tachycardia in adults. Cochrane Database Syst Rev 2006:CD005154. doi:10.1002\/14651858.CD005154.pub2","DOI":"10.1002\/14651858.CD005154.pub2"},{"key":"2020050721424934000_104.24.1993.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.resuscitation.2015.07.016"},{"key":"2020050721424934000_104.24.1993.6","first-page":"e506","article-title":"ACC\/AHA\/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"2016","author":"Page","year":"2015","journal-title":"Circulation"},{"key":"2020050721424934000_104.24.1993.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.resuscitation.2009.01.017"},{"key":"2020050721424934000_104.24.1993.8","unstructured":"Committee JF . British National Formulary (BNF) 74. London: BMJ Group and Pharmaceutical Press, 2017."}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2017-312909","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T18:20:09Z","timestamp":1601058009000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2017-312909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,14]]},"references-count":8,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2018,11,27]]},"published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1136\/heartjnl-2017-312909"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2017-312909","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"type":"print","value":"1355-6037"},{"type":"electronic","value":"1468-201X"}],"subject":[],"published":{"date-parts":[[2018,5,14]]}}}